US FDA approved Krintafel (tafenoquine) for the radical cure of P.vivax in malaria

//US FDA approved Krintafel (tafenoquine) for the radical cure of P.vivax in malaria

GSK and Medicines for Malaria Venture (MMV) today announced that the United States Food and Drug Administration (FDA) has approved, under Priority Review, single-dose Krintafel(tafenoquine) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection. Read more on their official website: https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-krintafel-tafenoquine-for-the-radical-cure-of-p-vivax-malaria/

By |2018-11-29T09:34:53+00:00July 23rd, 2018|

Leave A Comment